CSL’s Vaccine Shock: Stock Plunges to 7-Year Low Amid Shareholder Revolt
Vaccine Slump Triggers Profit Downgrade and 7-Year Share Low CSL – Australia’s fourth-largest public company – stunned the market by cutting its profit outlook and delaying a major spinoff due to a steep and unexpected decline in flu vaccinations in the United
